Viatris to Buy Pacira BioSciences for $1.65 Billion

Impact · against what's priced in

Viatris is acquiring Pacira BioSciences for $1.65 billion to expand its medicines portfolio. This is a material positive for Pacira via the acquisition premium and a strategic expansion for Viatris.

PCRA+0.60: No priced-in read yet
In context: The agreement to be acquired for $1.65 billion provides an immediate valuation catalyst for Pacira BioSciences.
Read from the article alone
Actual

Viatris to Buy Pacira BioSciences for $1.65 Billion

m and a
healthcare
PCRA
VTRS
acquisition
pharma

Search tags

Viatris to Buy Pacira BioSciences for $1.65 Billion

What matters in this story

How each ticker is affected

Futura Medical revises sale timetable as finance director steps down

Viatris to Buy Pacira BioSciences for $1.65 Billion

What matters in this story

How each ticker is affected

Futura Medical revises sale timetable as finance director steps down

Connected tickers

Track these names every morning.

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

Harrow: Q3 Needs To Prove The Turnaround Is Real

Market Concentration Is Spooking Wall Street—I'm Buying Kenvue

Viola Davis partners with GSK to educate adults 50 and older about their shingles risk

Viatris to Buy Pacira BioSciences for $1.65 Billion

What matters in this story

How each ticker is affected

Next reads from the same story arc

Futura Medical revises sale timetable as finance director steps down

Viatris to Buy Pacira BioSciences for $1.65 Billion

What matters in this story

How each ticker is affected

Next reads from the same story arc

Futura Medical revises sale timetable as finance director steps down

Connected tickers

Track these names every morning.

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

Harrow: Q3 Needs To Prove The Turnaround Is Real

Market Concentration Is Spooking Wall Street—I'm Buying Kenvue

Viola Davis partners with GSK to educate adults 50 and older about their shingles risk